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Section I: Title and Abstract
Abstract
Problem: According to The International Agency for Research on Cancer (IARC) 2020 World
Cancer Report, cancer has contributed to 9.6 million deaths in 2018 and is now globally
considered the second most common cause of death (IARC, 2020).
Context: As a cancer patient moves beyond diagnosis, there becomes a need to introduce the
plan of care and education related to evidence-based treatments with an intent to cure. As the
delivery of these treatments continues to move toward outpatient care, herein lies the challenge
of sharing important information with the patient to improve health outcomes.
Intervention: This DNP change of practice project used an evidence-based educational training
toolkit and educational endeavor targeting oncology nurse coordinators.
Measures: The author developed Nurse-Led Pre-Treatment Education Experience Survey that
was used to collect baseline data pre-and post-training to measure project outcomes.
Results: Thirteen Nurse Coordinators participated in this educational change of practice. It was
anticipated that through education and a toolkit, nurse knowledge would increase by 20 %. The
data analyzed after the intervention showed an increase in nurse knowledge of 35%.
Conclusion: The value of providing an educational toolkit for use by oncology nurses
has shown to improve knowledge and comfort levels for these providers and enable the patient to
self-manage potential treatment-related side effects.
Keywords: nurse, nurse coordinator, patient education, navigator, chemotherapy teaching
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The Nurse Will See You Now: Improving Nurse-Led Chemotherapy Teaching
Section II: Introduction
Background
Breast cancer has become the most prevalent cancer besides skin cancer to affect women
in the United States (American Society of Clinical Oncology [ASCO], 2019). According to the
National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER), it is
estimated that 268,600 (15.2%) new cases of female invasive breast cancer are expected to be
diagnosed in 2019, affecting about one in eight (12%) of women over their lifetime. Of those
diagnosed, it is estimated that 40,920 (6.7%) are expected to die (National Cancer Institute
[NIH], 2018). Fortunately, due to recent advances in life-saving treatments for breast cancer,
there are multiple options to offer the patient: surgery, radiation, chemotherapy, targeted
therapies, hormonal therapies, and clinical trials (Breastcancer.org, 2019).
Problem Description
Oncology care in an academic medical oncology outpatient setting is complex, requiring
multidisciplinary team-based models to give the most effective, safe, and efficient patient
care. The role of the oncology nurse coordinator (NC) or multidisciplinary care coordinator
(MCC) was developed to respond to this complex system. Navigation of the system has become
a standard of care by which cancer programs become accredited by the Commission on Cancer
(Swanson, Strusowski, Mack, & Degroot, 2012).
The oncology nurse coordinator role in a large academic outpatient oncology clinic is
continually being modified to better assist the patient care team in improving patient education.
After the plan of care is put together by the medical oncologist, along with input from the
patient, it becomes necessary to educate the patient on what to expect and how to manage this
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phase of treatment. This experience consists of pre-treatment care planning and conducting a
clinic visit to inform the chemotherapy-naive patient before treatment to potentially improve the
patient's overall treatment journey.
Setting
According to Oncology.stanford.edu. (2019) the specialized care offered in these
oncology clinics includes advanced treatment and supportive, compassionate care to treat every
stage of breast and gynecologic cancer, including genetic counseling, participation in clinical
trials, and survivorship support. The website states that they are family-centered and merge
advanced technology and team-based supportive care to assist patients with their treatment plans
(Oncology.stanford.edu, 2019). This team-based care includes an oncology nurse experienced in
treating cancer patients and is vital to the multidisciplinary care coordination program. Members
of this team include the Medical Doctor (MD), Advance Practice Provider (APP), Oncology
Nurse Coordinator (NC), Clinical Administrator (CAA), and Medical Assistant (MA). They all
play an essential role in helping personalize the treatment plan.
Nurse coordinators in this DNP student's clinic are not fully utilized as supportive clinical
professionals to help offload the educational burden from the APP to optimize team-based care.
A current high-level initiative in the Women's Cancer Center clinics to help transition the nurse
coordinator to be more patient-facing and involved with patient education is underway. This
project supports this focus to succeed by utilizing the NC to offload this educational visit from
the APP allowing the APP to increase their patient volume in independent clinics with a resulting
increase in financial viability for the clinic.
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Specific Aim

This project's global aim was to improve chemotherapy teaching for newly diagnosed
cancer patients by implementing standardized education and documentation to enable the nurse
in the outpatient clinical setting to teach the patient population competently. This DNP quality
improvement project introduced a clinic-specific toolkit in educational training for the nurses to
allow patients and caregivers to know what to expect during their chemotherapy routine and
improve the patient experience at the first treatment visit.
Improvements in this DNP student's local setting have allowed for expanded use in other
cancer outpatient clinics to help encourage the NC to independently teach the pre-treatment
education as the toolkit is easily modified for a specific cancer population. The project was
implemented in December 2019. Measurable project outcomes included:
RN knowledge base related to imperative information necessary to educate the patient
before the first treatment will increase by 20%.
RN knowledge base related to the nurse's role in conducting a pre-treatment educational
visit will increase by 20%.
RN knowledge base related to how the pre-treatment educational visit will be scheduled
will increase by 20%.
RN knowledge related to how to document the pre-treatment educational visit will
increase by 20%.
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Available Knowledge
PICO(T)

This review investigated and identified the current practice of oncology patient pretreatment education and strategies utilized to improve communication of this critical phase of the
patient's care. The following PICO(T) question was developed to direct the search for nurse-led
education's effectiveness and use of an evidence-based toolkit that would benefit patient care in
the oncology clinics at Stanford Healthcare: In the breast and gynecology oncology clinics, does
the use of a standardized chemotherapy teaching toolkit, as compared to no standardized process,
increase the nurse's effectiveness/confidence to conduct the patient's pre-treatment educational
clinic visit?
Search Methodology
I conducted a comprehensive literature review, utilizing the most up-to-date evidencebased information to justify and gather tools for this project. Topic-specific keywords were
used, such as a nurse, nurse coordinator, patient education, navigator, and chemotherapy
teaching. Databases searched included the Cumulative Index to Nursing and Allied Health Line
(CINAHL), PubMed, Oncology Nursing Society (ONS), Google Scholar, and Academy of
Oncology Nurse Navigators utilizing English-language material published between 2008 to 2020
Many systemic reviews and articles discussed how the nurse as a patient educator helped
increase patient satisfaction.
The extensive literature review identified approximately 20 articles with the potential to
be utilized for this process. Papers selected for inclusion were those most relevant to this author's
intervention and specific to the PICOT question. The Johns Hopkins Nursing Evidence
Appraisal tools were used (Dang & Dearholt, 2018) to identify the exact steps necessary to
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evaluate the evidence to determine the practice question and develop recommendations related to
practice change. A summary of the final eight articles deemed most relevant is presented below.
Review of the Literature
Jivraj et al. (2018) discussed how a nurse-led chemotherapy educational class increased
patient knowledge to decrease anxiety and made sure the patients had the necessary information
pre-treatment to reduce post-treatment confusion related to side effects. The authors reviewed
data at a large oncology cancer center over one month. Nurses collected metrics relating to 37
patients who started a new treatment. Post-treatment phone call logs showed that out of the 168
calls, 139 were related to symptom management, with six having to do with medication
questions and 23 about scheduling. With approximately 83% of needs related to symptoms, it
was determined that it would behoove the center to develop a tailored pre-treatment educational
class. The evidence-based material was gathered, and a course was designed to teach the
necessary information with a notable decrease in post-treatment patient-related questions.
Unfortunately, metrics were not collected, but according to the authors, the post
educational patient evaluations showed that individualized pre-treatment education was more
valuable concerning a broad group class than one that was not tailored to specific chemotherapy
agents. This project could help support a pre-treatment educational visit to help the patient gain
the necessary knowledge of treating post-treatment potential side-effects without sending a
message or calling the team with every concern. It also showed the value of giving this visit in an
individual format versus a generic class.
Mann (2011) conducted a quality improvement project, highlighting the benefits of
having the oncology nurse deliver the individualized pre-treatment patient teaching in a
controlled learning environment. This educational intervention aimed to improve the current
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system of providing education to newly diagnosed patients with cancer by assessing individual
patient needs and providing education before treatment. Methods included identifying two
groups of patients, Group A, those newly diagnosed and given the intervention (teaching by the
nurse), and Group B, former treatment patients who did not receive this teaching. Both groups
were then asked how the educational information from the nurse could be improved. The study
found that group A participants were overwhelmingly satisfied with the teaching.
In contrast, group B had numerous suggestions on improving the pre-treatment education
to navigate post-treatment sequelae. This study was helpful as it showed the importance of
utilizing an assessment tool to evaluate patient literacy level, reading skills, cultural or religious
aspects, available support systems, and anxiety levels before giving patients information about
their upcoming treatment. The data amassed in this study also shows that it would be beneficial
to conduct the NC educational visit before the first treatment and to individualize the education
to address specific needs and preferences.
An existing pre-treatment patient educational study was evaluated at a large academic
outpatient oncology facility. The author intended to see if eighty-one cancer patients and
caregivers who were shown a video followed by a nurse-facilitated group educational class
found this information helpful in managing post-treatment side effects. According to FeeSchroeder et al. (2013), this coordinated curriculum had previously not existed. Of those
participants who did not already begin chemotherapy, (n=42) was given an initial survey which
showed that 98 % of patients and caregivers felt the intervention increased their understanding of
side effects and how to manage them. Results also showed that 98 % felt this education increased
motivation to utilize self-management strategies such as increasing physical activity and fluid
intake, as well as modifying dietary behaviors. Other themes identified that the participants
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planned to modify their behavior and communicate more frequently with the medical team
regarding ways to cope. The survey was again completed at eight weeks, and 24 participants
(69%) reported they continued to use these strategies learned in the class.
The authors stressed the limitations included using a convenience sample in that the
chemotherapy class was optional, and those who did attend were potentially more motivated to
learn. The authors also did not assess the nurse discussion and video value separately, so benefits
could not be attributed to either intervention. Lastly, although the questionnaire was based on
prior patient surveys, it was not validated.
A randomized, controlled study by Aranda et al. (2011) was conducted to assess how pretreatment chemotherapy education would affect patient distress, treatment-related concerns, and
the severity of post-treatment side effects of patients commencing chemotherapy. One hundred
and ninety-two cancer patients were recruited to receive various educational interventions before
the first treatment (intervention 1), a follow-up telephone call 48 hours after the first treatment
(intervention 2), and a final in-person review immediately before the second treatment
(intervention 3). After measuring patient outcomes from baseline (T1) and before proceeding
with cycle 1 of treatment (T2) and cycle 2 (T3), it was found that patient distress was not
significantly reduced. However, they did find that these pre-treatment interventions did show a
significant decrease in psychological (P=0.027), procedural concerns (P=0.03), and a reduction
of symptoms of vomiting (P=0.001) by T3. Its findings suggest promise in that pre-treatment
chemotherapy education shows some improvement in patient treatment-related concerns along
with physical/psychological outcomes. They also recommend further research with more robust
patient populations to generalize the findings across varied settings.
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Dalby et al. (2013) discussed a process improvement project conducted by a team of
oncology nurses that utilized three interventions as "a checklist, a treatment-specific calendar,
and a patient education assessment survey" (p. 473). Patient satisfaction related to this education
was evaluated one month after implementation by distributing a five-point Likert-type scale
questionnaire to patients at their third treatment visit. This information helped guide follow-up
information specific to educational and written material to give to the patient. Outcomes reported
53 patients scored an average satisfaction score of 4.86 (on a scale of 0-5) regarding how patients
manage side effects after the intervention (Dalby et al., 2013). The most significant increase was
found regarding patients reporting what to expect during their treatment from a baseline score of
91% and how to manage side effects score of 87% with a post-intervention satisfaction score of
97% in both knowledge and ability to manage chemotherapy-related side effects. This study is
essential as it showed that utilizing materials such as checklists, calendars, and patient surveys,
which are readily available, may help increase patient satisfaction related to patient education. A
pre-treatment toolkit, which this DNP student compiled, would contain all relevant evidencebased material in an easy to utilize format.
Wagner et al. (2018) discussed whether newly diagnosed cancer patients have an
improvement in the quality of life and overall patient experience with the intervention of a nurse
navigator involved in their supportive care. Two hundred and fifty-one adult patients recently
diagnosed with breast, colorectal, or lung cancer were randomized to receive usual enhanced
care (n-=118) or nurse navigator support (n=133) for four months. The primary care physicians
were utilized as units of randomization in a two-group cluster-randomized, controlled trial. Selfreported measures from The Functional Assessment of Cancer Therapy-General (FACT-G),
Quality of Life scale, three subscales of the Patient Assessment of Chronic Illness Care (PACIC)
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were collected at baseline, four months, and 12 months via a self-reported experience survey.
According to the authors, baseline mean scores for the population were higher than for random
samples of adults with cancer (83 v 80). This finding, according to the authors, may be that the
cohort only consisted of patients who were receiving treatment with an intent to cure and not
palliative, and high socioeconomic status of the enrollees. The patients who received the nurse
navigator intervention had significantly higher scores on the PACIC summary scores as noted by
higher mean scores received at four and again at 12 months. Study limitations did include a
limited sample size. The authors concluded that nurse navigator support for patients with an
early diagnosis of cancer improves the patient experience and reduces care problems compared
with usual enhanced care. Still, the quality of life was not differentially affected.
A study conducted by Munoz, Farshidpour, Chaudhary, and Fathi (2018), found that
newly diagnosed cancer patients face challenges related to delays in care, lack of information,
and inadequate attention to emotional and social problems. Incorporating a cancer nurse
navigator helps to improve coordination and communication to increase patient satisfaction and
care. The purpose, as described by the authors, was to evaluate a multidisciplinary cancer care
model at two endpoints: (a) time from diagnosis to initiation of treatment and (b) an average
number of missed appointments.
This retrospective cohort study was completed to determine if an Oncology Nurse
Navigator (ONN) effectively improved these two variables. The experimental group included
patients assigned to an ONN, 34 men and 26 women. The control group was not given an ONN
and consisted of 35 men and 25 women. Findings suggest that an ONN's inclusion as part of the
multidisciplinary cancer care model experienced a significantly shorter time between diagnosis
to treatment (p < 0.001) than those not assigned an ONN. They also found no statistical
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difference in missed appointments between the two groups (p = 0.7). Findings further established
that the ONN's inclusion helped facilitate the number of patients referred to the multidisciplinary
tumor board review. Patients referred to the tumor board have shown to have better outcomes.
Lastly, the authors discussed a potential bias within the study because it was conducted within a
multidisciplinary cancer care model, and that reality may have affected outcomes as
multidisciplinary care centers tend to have higher levels of care in general.
Apor et al. (2017) gave oncology patients a pre-evaluation survey to assess their
perceived understanding of various treatment topics after discussing the proposed treatment with
their medical oncologist. The patients then received teaching by an oncology nurse, and the
survey was re-administered when they returned for their first and second treatment cycles. The
goal was to evaluate the effect of a nurse-led chemotherapy teaching session on the patient's
knowledge, anxiety, and feeling of being prepared for the treatments. As noted by the authors,
one hundred and ninety-six patients enrolled in the study and completed a survey before their
teaching. One hundred eighty-two patients completed the survey again before cycle one. Finally,
a third survey was conducted by one hundred and seventy-one patients. Responses noted at the
second cycle of chemotherapy showed no statistically significant decrease in how patients felt
contacting a physician caused them to feel anxious (p=0.0801) or how treatment-related side
effects caused anxiety (p=0.2737). Statistically significant increases were observed in three
patient indicators such as patients' perceived knowledge of the treatment schedule, potential side
effects, and medications to help prevent treatment-related side effects ( p= <0.001). Study
limitations, as noted by the authors, were that the survey instrument was not previously
validated. A group of clinical oncologists reviewed the tool for construct and content validity
before initiation to address this lack of validity. Also, the authors did not collect information
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related to the patient's disease stage. This information may have affected the results as some
stages are not curable, and only palliative options were available to the patient.
Summary of the Evidence
Much heterogeneity exists in the literature and suggests that a well-structured
educational intervention related to the NC teaching pre-treatment information to chemotherapy
naïve patients helps increase patient knowledge and decrease anxiety. This education has the
added benefit of enabling the patient to self-manage common treatment-related side effects.
However, few articles discussed how a nurse navigator educating patients was a cost-effective
method and how nurses felt their educator's role helped the navigation process. A summary of
the most relevant evidence is presented in an evaluation table (Appendix C for Literature Review
Evaluation Table).
Rationale
A well-developed planning model such as Precede-Proceed enabled the process to be
more effective and efficient. This model was first proposed in 1974 by Lawrence W. Green, a
public health education specialist, as an evaluation framework. It became known as Precede in
1980 and later expanded upon by Green and Kreuter in 1991 to include Proceed (Porter, 2016).
This model, as explained by Connon and Salazar (2004), utilizes the stages of assessment
(Precede) and intervention (Proceed) by breaking it down to understand further the key elements
such as policies, regulations, and resources in play that will either benefit or hinder the measure.
The authors also identify the five types of assessment required to adequately "diagnose" the
population's unique needs before proceeding, such as social, epidemiologic,
behavioral/environmental, educational/organizational, and administrative/policy. Concerning
social diagnosis, assessing the population's perception of its own needs is necessary. The
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population related to this DNP project are the stakeholders involved in making this plan a
success along with the oncology patients it will affect. As previously discussed, the staff
educated on the toolkit are the NCs in the oncology clinics, which utilized the information to
teach newly diagnosed cancer patients the most relevant, evidence-based information before they
commenced their first treatment.
The determination of which health problems are of the most significant concern to the
population were epidemiologic. This included breast and gynecological newly diagnosed patients
with cancer who will receive treatments to help "cure" or potentially decrease the risk of cancer
recurring and/or becoming "incurable." Behavioral/environmental, as determined by the authors,
would identify which problems would have the most significant importance to the population.
For this change of process project, it is helpful to identify stakeholders’ attitudes, knowledge,
and beliefs related to reinforcing reward and enabling factors that would support cultural change.
According to Melnyk and Fineout-Overholt (2011), a culture of "best practice" would need to be
established to consistently implement EBP in healthcare organizations. Regardless of their
educational status, all nursing staff should be educated and encouraged to utilize evidence-based
practice. The authors suggest that it is also helpful to have EBP mentors to help implement and
sustain an EBP culture.
As a DNP student in an academic healthcare system, I conducted a presentation early in
the process regarding a process improvement plan to clinic stakeholders to introduce and define
the project. It was necessary to include information related to how utilizing EBP when
undertaking a program such as this was important to ensure patients receive the most relevant
information. Learning how to conduct an improvement plan and how to use evidence-based
processes will help the staff feel they have a stake in the outcome and success.
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Educational/organizational diagnosis relates to establishing how the stakeholders feel
their education and skills will enable them to adequately teach the patient population. It also may
refer to how they feel the organization has equipped them with the most useful tools to utilize in
teaching the patient. The change of process plan educated the stakeholders and encouraged the
use of a standardized, evidence-based toolkit.
Lastly, identifying policies, regulations, and resources that would either hinder or
enhance implementation is referred to as administrative policy (Connon & Salazar, 2004). This is
best accomplished by involving leadership, clinical educators, and internet technologists (IT) to
distinguish what information is appropriate to utilize with Stanford Healthcare branding and how
to potentially bill for the NC pre-teaching visit. For this process improvement plan, this author
used leadership to advise regarding the overall scope and potential resources that could be tapped
into to support the project. The oncology nurse educator was then introduced to this project with
an aim to increase the project's breadth and communicate the author’s intention along with
reaching out to other oncology clinics at Stanford Healthcare. IT educators were then involved in
designing an electronic version of the toolkit to share this information more easily via electronic
means, help with literacy review and language development.
After assessing the population, the authors suggest moving on to the proceed measure of
the model. This includes planning, implementation, and evaluation. It is known that making
decisions about behaviors is sometimes complicated. The model considers this complexity and
helps set priorities and determination making in a systematic approach to include
implementation, process and impact, and outcome evaluation.
As further described by Crosby and Noar (2011), this planning model would help explain
the phenomenon of conducting a process improvement project and identifying measurable
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variables as it enables to serve as an organizing framework aimed at a health promotion effort.
The model follows the critical point in the process of planning "backward," meaning that it
illustrates "working from the end goal to produce objectives and sub-objectives that, if met, will
culminate in the realization of that goal" (p. S9), contributing to a logical endpoint.
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Section III: Methods
Context
Clinic leadership must ensure staff has adequate education, resources, and support to
provide exceptional, competent, and safe care. As an independent, not-for-profit organization,
The Joint Commission (2018) certifies healthcare organizations nationwide to maintain specific
performance standards. Their mission is to improve the public's health by continuously
evaluating healthcare organizations and inspiring them to provide safe, effective care of the
highest quality and standards. Dickson (2018) further described that accreditation organizations
such as the Joint Commission help organizations improve care quality by reducing process
variation across organizations.
Stanford Healthcare, as a Magnet© designated facility, and according to its website,
Stanford HealthCare (2019) would be responsible for ensuring its nurses had adequate education
development to provide greater autonomy to deliver the best care. Furthermore, according to
the American Association of Colleges of Nursing (AACN) (2018), Doctor of Nursing Practice
(DNP) educated nurses are well prepared to provide evidence-based, quality improvement
project management initiatives to improve patient outcomes. The research confirms this
statement as multiple studies show a 10 percent increase in baccalaureate-prepared nurses
involved in patient care, showed a nine percent decrease in patient deaths. Advanced nursing
education has a significant impact on nurses' knowledge and competencies and, therefore, their
value to the practice setting (AACN, 2018). This data suggest a DNP student is well equipped to
lead process improvement interventions. This successful change of practice in the Women's
Cancer Center, Stanford Healthcare local setting has also effectively brought about
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improvements in patient care education in other oncology clinics through modification and use
of this educational endeavor.
Ultimately, patients were most affected using this process improvement change as they
benefitted from getting appropriate evidence-based, individualized treatment education and
toolkit materials to reference. Key stakeholders related to this process improvement plan were
the nurses directly impacted by this change in their NC role. Medical providers such as
physicians or APP's were also affected as traditionally; the APP gave the pre-treatment education
after the physician went over the patient's plan of care. Supportive personnel such as clinical,
administrative assistants/ medical assistants are also affected. They helped ensure toolkit
availability by providing the necessary information that is readily available for the NC to access
and send the toolkit to the patient's home if needed. Clinic leadership in the cancer center is also
critical as it was necessary to gain their approval and provide essential resources to succeed (See
Appendix B for Agency Letter of Support).
Interventions
I intended to improve the process related to NC chemotherapy teaching through
standardized education and documentation to enable the nurse in the outpatient clinical setting to
teach the patient population and enhance the patient experience at the first treatment visit. The
intervention was chosen to positively impact multiple aspects of the workflow and fill
knowledge gaps associated with chemotherapy teaching.
To gain information about the mesosystem that makes up Stanford Healthcare's
outpatient oncology clinics, I moderated a focus group that included 19 NCs from other Stanford
oncology clinics and infusion areas. The intent was to explore the current state of patient
education and teaching along with introducing this process improvement plan. Themes identified
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from the well-attended class included: (a) aligning all groups and roles in standardizing
chemotherapy regimen teaching (specific chemotherapy regimen teaching and general teaching),
(b) provide alternative delivery methods (video, binders, 1:1 teaching, group session), (c) How to
sustain the educational system so that it will not become obsolete (See Appendix N for Focus
Group Information).
A PowerPoint presentation was conducted for clinic leadership and stakeholders in the
breast and gynecology cancer clinics to introduce the intervention, define the quality
improvement process, explain the importance of pre-treatment education, review the research,
and discuss recommendations going forward. Qualitative information was collected related to
nurses' feelings and observations regarding how they felt conducting an educational teaching
visit with currently available knowledge and materials.
A toolkit was developed for nurses and patients to utilize when conducting the pretreatment chemotherapy session. It was requested from clinic leadership that the author develop a
nurse-specific checklist to ensure that the nurses had standardized information available to teach
the patients. The project's projected implementation was January 2020, after developing the
manuscript and prospectus, which was completed in June 2019.
The project included 1:1 educational training of the nurses, which lasted approximately
45 minutes. Some nurses required additional education depending on their level of comfort with
patient education and prior work experience. Some nurses found it helpful to sit in on an
educational visit with the author to observe prior to conducting an independent teaching session.
Gap Analysis
According to Fee-Schroeder et al. (2018), educating patients about their chemotherapy
treatments and potential side effects is standard practice in most cancer centers. According to the
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Oncology Nursing Society, it is also a standard of care (Neuss et al., 2017). I conducted a gap
analysis before initiating this project with an intention to assess and analyze the current state of
NCs role in teaching chemotherapy naïve patient's pre-treatment education. All aspects of this
analysis of chemotherapy teaching's current process were completed in collaboration with key
stakeholders involved in the teaching process.
Nurse coordinators in these clinics are not fully utilized as supportive clinical
professionals to help offload the educational burden from the APP to optimize team-based care.
A current high-level initiative in the women's cancer center clinics encouraging nurse
coordinators to utilize their education and skills at the highest level to educate its patient
population has helped transition the nurses to be more engaged and patient-facing. It would
behoove leadership to support a process improvement plan to help move in that direction. It is
anticipated that this process improvement plan with the implementation of a unit-specific toolkit
will positively impact multiple aspects of the workflow and fill knowledge gaps associated with
chemotherapy teaching.
Four objectives were identified from the formal gap analysis: (a) identify information
clinic nurse coordinators would deem necessary to conduct a pre-treatment educational visit, (b)
develop specific information to be included in the teaching toolkit, (c) improve communication
related to the availability of supplemental resources, (d) develop a sustainability plan for current
and future resource management along with identifying personnel who will take responsibility of
compiling and maintaining the materials (See Appendix D for Gap Analysis).
Gantt Chart
A Gantt chart was then developed to illustrate the timeline related to specific tasks and
complete all milestones on schedule for the project. According to Mindtools (2018), this visual
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chart can easily be modified and presented to other stakeholders in an easy-to-understand format.
The project deliverables are listed on the left, with dates on top to estimate timelines. The project
started with a basic literature review and gap analysis. The aim was to carefully determine the
problem gaps between current and desired practice and determine if the literature supported an
evidence-based change to improve patient outcomes by developing a toolkit to enhance nurse
coordinator education. The "gap" was then be formulated into a PICO question, and the problem
was further refined to be kept narrow in focus. More extensive and specific literature reviews
were then conducted utilizing search terms from the PICO question. Stakeholders particular to
the process improvement plan were identified. A proposal to critical leadership was completed to
assure buy-in for the strategy and assure the project would be well-aligned with the healthcare
organization's mission and goals.
The following steps were then completed and included a plan-specific timeline or work
breakdown structure, responsibility /communication matrix, SWOT analysis, and budget. This
information was then submitted in a draft of the proposal to the author’s DNP chair and the
second reader to review and was modified as needed. Implementation of the project commenced
after conducting an anonymous four-question Likert scale NC Pre-treatment education survey of
NCs in the breast and gynecology oncology units, who were responsible for taking on this
educational endeavor.
After developing the toolkit and education to support it, the survey was again conducted
to compare and determine if there was a positive correlation between the intervention and the
project outcomes. Lastly, the findings' summary report was presented to all key stakeholders, and
recommendations were assessed for future development (See Appendix E for Gantt Chart).
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Work Breakdown Structure
The work breakdown structure (WBS) is an organized example of the typical flow of a
"systems development project." According to the University of California Santa Cruz (2019), its
methodology is broken down into five work stages: Defining, Planning, Launching, Managing,
and Closing to describe a set of activities or deliverables that help move the project forward.
Completing a schedule such as this helps organize, define, and tailor the work into more
manageable increments.
In the first phase (define), strategies for identifying the evidence-based question were
identified by gathering internal evidence and developing a PICO question. A comprehensive,
systematic literature review was conducted utilizing the PICO components to answer the PICO
question effectively and efficiently (Melnyk, Gallagher-Ford & Fineout-Overholt, 2017). As
discussed by Dearholt and Dang (2018), the use of the Johns Hopkins Evidence Appraisal Tools
helped to critically appraise the most relevant evidence for use in this review. This phase
concluded by presenting the proposal and executive summary to the critical leadership for
approval and recommendations going forward.
The (plan) or second stage included establishing key stakeholders, developing
deliverables, and defining milestones to be reached. The toolkit development needed a small
team of nurses and APP's who worked in the clinic and had experience conducting prechemotherapy teaching. A project team kickoff meeting took place as I presented the plan to the
breast and gynecology oncology clinics' stakeholders to help communicate my intention. It was
recommended that I develop a checklist to ensure consistency in the nurse's teaching.
A focus group meeting was arranged with the help of the cancer center nurse educator.
He helped coordinate with nurses from other cancer clinics and infusions areas. This meeting

28
was helpful as I learned how other nurses were conducting pre-treatment teaching and
communicated my intention to a broad scope of oncology clinic nurses.
The third stage (launch) included a breakdown of the project workflow to ensure that
project deliverables and milestones were achieved. The first deliverable was creating a written
toolkit that included evidence-based information related to managing post-treatment-related
symptoms, miscellaneous information, and phone numbers. I then developed a nurse knowledge
and attitude survey to give the nurses before 1:1 education and training. The project was
implemented in January 2020.
The fourth stage (manage) included using PDSA cycles to ensure necessary
modifications were addressed and change to help the process succeed (IHI,2019). This phase of
the project was ultimately slowed due to COVID-19 and difficulty completing the nurses'
necessary education. After frequent discussion via remote evaluation meetings, the post-survey
tool was then completed by the nurses.
The final phase (closeout) consisted of measurement of data and evaluation utilizing
Excel software to determine the patient improvement project's success. A sustainability plan was
developed, and further modifications were discussed to help make the toolkit more accessible via
an electronic version and conduct the clinic visit via remote modalities. A final wrap of the
project and resulting data was presented to the stakeholders (See Appendix F for Work
Breakdown Structure).
Responsibility Matrix
The project stakeholders' roles and responsibilities are delineated in the responsibility
matrix. Specific functions were delegated to include the project unit leader, DNP student, nurse
coordinators, and APPs who function as nurse practitioners (NPs) or physician assistants (PAs),
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along with medical oncologists. Other significant players included unit leadership and ancillary
staff such as clinical, administrative personal, medical assistants, and finally, front desk
personnel who work to check patients in and out of the clinic. Recognition of the vital members
is a critical part of the project because it delineates all persons and their responsibilities related to
the project scope, roles, commitment, and timelines (See Appendix G for Responsibility Plan).
Communication Matrix
It was essential to communicate imperative information to persons at the right time. This
communication plan was developed and managed by the DNP candidate to ensure that the
project remained within scope, on time, and on budget. The project was initially proposed to
clinic leadership via an in-person meeting to provide an overview of the specific goals and
potential impact this process improvement plan would have on improving nurse-led prechemotherapy teaching.
This project, along with information related to how an evidence-based project can help to
improve patient care, was discussed during a presentation to stakeholders with an intent to show
energy and help engage the staff early in the process. Ongoing feedback was also facilitated at
daily huddles and monthly staff meetings to amend the information in real-time and make
relevant changes to improve the process. Several edits were made to the toolkit as relative
information was recommended by staff to make sure necessary information was contained to
relay to patients prior to starting treatment (See Appendix H for Communication Matrix).
SWOT Analysis
The development of a SWOT analysis was completed to analyze the potential strengths,
weaknesses, opportunities, and possible threats to this intervention. It helped create full
awareness of the environment and take a proactive approach to enable the project to succeed.
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One such strength this author identified is strong leadership support to allow the NC to
independently teach the pre-treatment educational visit. As a large academic institution, the
organization encourages nurse leaders to implement evidence-based project improvements. As a
Magnet-designated facility, the organization's strategic goals align with American Nurses
Credentialing Center (ANCC) to improve patient outcomes (ANCC, 2018).
One internal weakness that was identified is the lack of clinical administrative assistant
(CAA) support personnel to offload the nurse's non-clinical aspects of their workflow. NC
workflow must be managed to allow them the time to educate the patient adequately. An
endeavor is currently being implemented in the clinics to help transition these non-nursing tasks
to CAA's and enable the NC to be more patient-facing.
Through this analysis, identified opportunities exist to potentially advertise the role of
NC as an integral asset to the team-based Care that Stanford Healthcare gives its patients.
Utilizing an NC to assist its patient population in pre-treatment education represents
a competitive edge. Other extensive healthcare facilities in the Bay area do not currently employ
a clinical professional in this role. This comprehensive individualized education may also have
an impact on patient satisfaction scores that will benefit the organization.
Finally, threats would be the possibility of leadership modifying the team-based role the
NC currently plays into more of a triage nurse who is less involved in a point-of-care team-based
patient teaching. Patient pre-treatment education would then transition to a group session not
specific to its treatment plan (See Appendix I for SWOT Analysis).
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Budget
This project’s budget was designed using an implementation strategy to introduce new
education to NC’s and the use of a toolkit with an aim to improve knowledge and comfort levels
related to how the nurse educates patients starting new treatments. The process improvement
plan's direct and indirect costs to develop and implement the project were essential information
when considering this process change. The direct costs comprised personnel time related to
creating this plan and educating the nurses involved during implementation. The average
registered nurse hourly rate, including benefits, according to the manager of these clinics, is
approximately 94.00/hr. When the time estimated is 30 minutes educational 1:1 session, the cost
associated with educating 13 nurses would be $611.00. The estimated time for developing the
toolkit, including pre-and post-surveys and follow-up PDSA, post-implementing of data and its
related analysis, costing approximately $22,184.00. Time spent communicating the project
proposal to leadership with an average nurse executive salary hour of $114.00/hour, over two 30minute meetings cost roughly $114.00. Indirect costs include printing surveys and reference tools
along with a folder that makes up the toolkit, which costs approximately $330.00. Total
estimated costs associated with this 3-month rollout would cost around $ 23,239.00 (See
Appendix J for Budget).
Cost/Benefit/Breakeven Analysis
I developed the educational material, and practicum hours were utilized on time spent
implementing the project. Costs to produce and implement this project totaled approximately
$23,239.00. Educating the NC was completed during 1:1 session time, and staff were kept
updated at daily huddles and monthly unit-based committee meetings.
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Although it is difficult to place a monetary value associated with this improvement
process, its value on the investment (VOI) is evident. The proposed benefits associated with
improving nurse coordinator teaching and resulting increase in the patient’s ability to selfmanage post-treatment care are universally positive outcomes. Stanford Healthcare would see
measurable revenue benefits to the health system by expanding nursing roles and allowing the
nurse to complete pre-treatment education. By the NC taking over the educational components,
the APP would be available to see at least one additional patient per day. Based on the ability for
the APP to be able to take one extra patient a day where it can be billed at $1,200, it would take
19.37 patients to break even with the costs of the project ($23,239.00/$1,200=19.37).
It is anticipated that this standardized education and toolkit will also improve nurse
engagement as a supportive team member in the clinic and potentially reduce nurse turnover in
the role. The literature supports this assertion as it has been shown by Wan, Li, Zhou, & Shang
(2018) that links between nurse turnover have been shown to be decreased through the
development of interventions to support the work environment. These nurse-led clinics also
provide a professional environment where nurses feel empowered in the multidisciplinary role,
and it is anticipated that nurse retention could improve due to increased satisfaction in the role as
an integral part of the patient’s multidisciplinary care team.
Return on Investment
Dividing the project's anticipated net income by the cost of the investment, you would
obtain a return on investment (ROI) calculation. For this educational improvement plan, the
expected net revenue could be as much as $288,000.00 over 12 months divided by its cost of
implementation $23,239.00 with a 12.4 percent ROI.
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Revenue
Over time it is expected that the project will continue to show improved patient
outcomes, and costs associated will decrease as upfront costs related to development and
implementation is complete with periodic review and improvements to be made. With reduced
average patient contact time spent by the APP educating the patient and offloading this to the
nurse coordinator will allow for the APP to see an additional patient per clinic day, which at the
current rate of $1,200 per visit would equate to an additional $288,000.
Additionally, there is also a potential for the NC to bill for caregiver education under
Medicare Part B utilizing education codes and documentation supporting the level of work
performed using a Level 3 or 4 Visit RVU. As noted by (Centers for Medicare & Medicaid
Services [CMS], 2020), this may generate approximately $25-35 charges per visit, which could
equate to as much as $6000 over a year’s time (See Appendix K for Expected Revenue).
Study of the Intervention
This project required a review of the existing practices in two large academic oncology
outpatient clinics to assess how patients received education prior to starting new chemotherapy
treatments. I then developed a toolkit that contained evidence-based materials that were highly
significant to oncology patient care. The use of the information contained in the final toolkit
materials was determined to be relevant after review by leadership and clinic colleagues.
I led a kickoff meeting for the stakeholders with the intent to introduce the QI project.
Education was shared on how evidence-based projects are conducted following the Institute of
Healthcare Improvement’s Model of Improvement (IHI, 2021). Gap analysis, project
management, and Plan-Do-Study-Act (PDSA) cycles were introduced. It was determined after
this presentation that a nurse coordinator checklist should be developed for use in determining
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that all necessary information is standardized and utilized in the education component (See
Appendix 0 for Pre-Treatment Nurse Checklist).
After implementation of the project, comparisons were made between the nurse’s
perception of how they felt this education and toolkit would help them independently teach and
document pre-treatment patient education, along with how this increased knowledge would
positively impact their workflow as nurse coordinators. Evaluation of the change of practice
DNP project required the use of a de novo evaluation tool that I developed to help determine
outcome measures related to the intervention. This tool is without established validity or
reliability but has shown to be a valuable lesson learned in evaluating this project.
Outcome Measures
Data Collection Tools
This project's primary outcome measures included an anonymous [pre-and postintervention] Nurse-Led Pre-Treatment Teaching Education Experience Survey, consisting of a
4-item author-developed Clinic Specific Toolkit Feedback Survey. The survey was developed
and delivered to the breast and gynecology nurses at the monthly cancer clinic-based meeting
and served as the tool development process. It included clinic-specific knowledge, preparedness
with teaching, documenting, and perception of the teaching visit. Responses ranged on a 4-point
Likert-type scale from "Strongly Agree" to "Strongly Disagree." Two open-ended questions were
also included to gain a perception of the challenges of conducting this educational visit, along
with suggestions to improve satisfaction (See Appendix L for Data Collection Tools).
Analysis
The project's participants included (N=13) nurse coordinators working in breast and
gynecological outpatient cancer clinics at Stanford Healthcare. APPs were not utilized in the data
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as I wanted to focus solely on how the change in process would affect the nurses in those
microsystems who will be adapting this change in practice. The pre-intervention survey results
were used as a baseline for the current perception of a nurse-led pre-treatment teaching
experience. Quantitative analysis was compared from the pre- and post-surveys with results
imported into an Excel spreadsheet. Descriptive statistics were used to analyze the data.
Information obtained from the pre-and post-survey qualitative data was used to inform and
understand how nurse perception of the training affected their knowledge and comfort levels as a
nurse coordinator and patient educator. The positive findings show that the educational
information and basic tenets of this toolkit could be easily modified and adapted in other clinics
across Stanford’s outpatient macrosystem. It is also anticipated that the information could easily
be modified over time and adapted as new evidence was received.
Ethical Considerations
According to American Nurses Association (ANA) (2017), the nurse's code of ethics and
human rights statement dictates that nursing must observe a patient's dignity and human rights
while committing to protect and promote social justice. This quality improvement (QI) process
improves the nurse coordinator's ability to conduct a pre-treatment educational visit that respects
the participant's privacy and dignity.
It is ethically and morally right for patients to expect the best evidence-based information
to manage anxiety and potential post-depressive symptoms after receiving the recommended
cancer treatments. The appropriate care does not stop after the patient decides to commence with
treatment. This is when the most impact can be made to help the patient become educated and
proactive to decrease an unpleasant experience. Without this information, the patient may
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experience side effects that contribute to discontinuing treatment before it is recommended and
have the cancer progress to an uncurable stage.
As a DNP student attending a school that aligns with the Jesuit faith's values and ethics, I
feel this project incorporated those practices of cura personalis-care of the whole person and
brought forth multiple components of caring for the patient (USFCA, 2019). Implementing
education to nurses with the goal of enabling the patient to utilize self-care interventions with a
resultant decrease in anxiety fulfills a core tenet of the Jesuit faith. The nurse-patient bond is also
strengthened as this teaching enables human interaction to be accomplished in a caring manner.
The process for gaining approval for conducting this change in process evidence-based
improvement plan involved obtaining authorization from both the University of San Francisco
and Stanford Healthcare. The university's SONHP DNP committee determined this project
exempt from the Institutional Review to protect human subjects (IRB) after reviewing the
student’s statement of determination. The project was deemed a process improvement project.
Stanford Healthcare, specifically the Women's Cancer Center oncology leadership, also
supported this project and discussed this and future publications. As a quality improvement
project, all information and data obtained will remain compliant with the Health Insurance
Portability and Accountability Act (HIPAA) laws and does not show a conflict of interest (See
Appendix A for IRB Document).
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Section IV: Results
Qualitative Findings
Information obtained from the Oncology clinic focus group showed common themes
aligning all groups and roles to standardize chemotherapy regimen teaching throughout the
oncology clinics and treatment areas. It would help provide alternative delivery methods and
ensure that the educational system would not become obsolete. The project was introduced to the
stakeholders via a PowerPoint presentation. Leadership found it necessary that a checklist be
developed to ensure the nurses were teaching information in a standardized approach.
The pre-treatment teaching education experience survey contained two open narrative
questions and information suggests:
Increased ability to teach this oncology population will lead to reduced post-treatment
patient messaging and pre-treatment anxiety.
The NC role would be highlighted as a member of the patient's team.
This educational visit early in the treatment allows the NC to establish a positive nursepatient relationship and become an essential resource. This visit helps to create a more
collaborative relationship that benefits both the patient and the nurse.
Allows the nurse to practice more fully within their scope of practice and reach their
potential as a healthcare provider.
Quantitative findings
Thirteen nurse coordinators from the Breast and Gynecology oncology clinics were
invited to participate in this educational endeavor. They were given a pre-and post-educational
survey utilizing a four-point Likert scale ranging from strongly agree to strongly disagree.
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Four questions evaluated how comfortable the nurses were with the current state of
nurse-led pre-treatment education. The questions focused on what was expected, specific
information needed to teach, and how to schedule the patient and document accordingly (see
results of the pre-education survey in Table 1 below).
Table 1.
Pre-Education Survey
Question (Range = 0.00 to 4.0)

Mean
Mean

SD
SD

I know what is expected of me in conducting an independent
nurse pre-treatment patient educational visit.

2.90

0.86

I know what specific information should be included in the
nurse pre-treatment patient educational visit.

2.80

0.89

I understand the process related to how a patient is scheduled for the
nurse pre-treatment patient educational visit.

2.40

0.65

I understand the process of how to document the information from the
nurse pre-treatment patient educational visit in EPIC.

2.50

0.77

The mean scores documented were less than 3 for all the questions, suggesting that the
nurses did not feel they had the knowledge and materials to conduct the patient teaching and
schedule and document the visit. Although the nurses have experience working with oncology
patients in the clinics, the findings suggest that they would need training regarding how to best
educate patients before starting treatment.
The post-nurse education/toolkit development scores showed improvements in all areas
of conducting the pre-treatment educational visit with increased mean values greater than 3 (see
Table 2 below).
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Table 2.
Post-Education Survey
Question (Range = 0.00 to 4.0)

Mean

SD
Mean

SD
I know what is expected of me in conducting an independent
nurse pre-treatment patient educational visit.

3.60

0.50

I know what specific information should be included in the
nurse pre-treatment patient educational visit.

3.70

0.48

I understand the process related to how a patient is scheduled for the
nurse pre-treatment patient educational visit.

3.50

0.51

I understand the process of how to document the information from the
nurse pre-treatment patient educational visit in EPIC.

3.50

0.51

I then completed a t-test to determine if the scores obtained were due to the educational
endeavor and not by chance. A statistical significance was set at p<0.05. The t-test, p-value
results indicate that the data received pre-and post-survey were statistically significant for all
questions (see Table 3 below).

Table 3
Statistical Significance Pre-Post Test
Participants
(N=13)

Question
1 Pre

Question
1 Post

Question
2 Pre

Question
2 Post

Question
3 Pre

Question
3 Post

Question
4 Pre

Question
4 Post

Mean

2.92

3.62

2.85

3.69

2.38

3.54

2.54

3.46

Std. Deviation
t-test,
p-value

0.86

0.51

0.90

0.48

0.65

0.52

0.78

0.52

0.02

0.01

0.01

0.01
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To follow the nurse's perceptions and feelings related to conducting a patient pretreatment educational visit over time, I engaged the support of clinic leadership to have the
nurses complete a follow-up survey in the following months. It is essential to continue to assess
if the toolkit information is up to date and supports current evidence (See Appendix M for Preand Post-Survey Results).
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Section V: Discussion
Summary
Data to support the project shows that project aims were met. See discussion below.
Aim one: Achieve more than 20 percent increase in RN knowledge base related to
imperative information necessary to educate the patient before the first treatment. Comparing
data from the pre-and post-survey questions indicated a rise of 24 % related to what information
was essential to discuss with the patient at the pre-treatment educational visit.
Aim two: Achieve more than > 20 percent increase in RN knowledge related to the
nurse's role in conducting an independent pre-treatment educational visit. Data obtained from
pre-and post-survey questions showed a rise of 32 % of how the nurses felt they were
knowledgeable about their role in conducting this educational visit.
Aim three: Achieve more than 20 percent increase in RN knowledge related to
scheduling the pre-treatment educational visit. This question had the most significant increase
in nurse knowledge associated with preparing the educational visit as the data showed a rise of
46 %.
Aim four: Achieve more than 20 percent increase in RN knowledge related to the pretreatment educational visit documentation. This question and the data amassed showed a rise of
40 % of nurses' understanding of documenting the pre-treatment clinic visit.
Overall, the data demonstrate an increase in nurse knowledge of 35%. This positive
statistic shows this DNP student met the goals of increasing nurse knowledge by 20% to take on
this educational endeavor. This project's success in the Stanford Healthcare breast and
gynecological oncology clinics helps potentially bring about positive change related to the role
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of NC. This change in process could also be adapted for use in other oncology clinics throughout
the system.
It is anticipated that this improved pre-treatment education will enhance the overall
patient experience and strengthen the nurse-patient bond as this evidence-based communication
shows compassion and empathy related to helping the patient manage treatment-related side
effects. Increased communication between the treating team and the patient will help encourage
the patient to reach out to the clinic if they are unable to self-manage treatment-related side
effects. The information included in the toolkit encourages the patient to notify the clinic or
after-hours nurse line if they felt they needed additional recommendations. Utilizing established
outpatient resources may help to decrease hospital ED visits as many concerns could be
addressed by the treating team or triage nurse before needing admission to the hospital. This may
help decrease overall healthcare costs upstream. It might be of value to conduct a retrospective
review of the data to see how this relationship may affect patient outcomes and patient
satisfaction scores.
Interpretation
As a cancer patient moves beyond diagnosis, there becomes a need for the provider to
introduce the plan of care along with education related to evidence-based treatments to give the
patient the best curative chance. As the delivery of these treatments continues to move toward
outpatient care, herein lies the challenge of sharing important information with the patient to
improve health outcomes.
The oncology nurse's ability to educate its patient population as part of the
interprofessional clinical team should not be taken for granted. Not all nurses are well prepared
to take on this endeavor. Adapting and embracing the role of patient educator as a fundamental
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nursing responsibility, with the proper preparation, will give the nurse the ability to shape patient
outcomes along with their primary care environment (Marshall & Sigma Theta Tau, 2016). The
challenge then becomes how to communicate this information before the patient commences
with treatment effectively.
Patients are willing to take steps to effectively self-manage the side effects of cancer
treatments if they are empowered with evidence-based information and tools. As a result of
increased awareness of how to lessen unpleasant symptoms, we also anticipate increased
compliance and improved health outcomes.
Limitations
There were limitations encountered regarding the implementation of the project. This
author initially anticipated to teach the nurses and pilot the intervention over three months, but
due to Covid-19 implications, the author extended this aspect of implementation to
approximately five months. As noted by the CDC and other governmental agencies, it was
recommended to conduct work via remote modalities and stay at home to avoid illness spread
and exposure (CDC, 2020). Stanford Healthcare mandated staff to take time off to help with the
institutional budget and transition to remote work. This made it challenging to communicate
effectively with the nurses and encourage them to conduct pre-treatment educational visits.
Some promising outcomes of remote work included the necessity of conducting some
patient care sessions via online modalities, such as Zoom or Video Visits. These online visits
allowed us to modify our workflow to accommodate patients that may live far or have concerns
with in-person clinical or educational visits and is a process that we anticipate continuing postCOVID-19 pandemic.
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Conclusions
This project aimed to develop, implement, and evaluate the effectiveness of using unitspecific education and tools to improve the NC's ability to conduct a pre-treatment educational
visit for newly diagnosed cancer patients in outpatient cancer clinics. The project was supported
and developed using the best available evidence-based information, current literature, and
established project management methods. This standardized toolkit enables the NC to schedule
and efficiently teach a patient necessary information and, in turn, adequately document this in the
patient's electronic health record (EHR). This change of practice positively affects NC workflow
as the NC now has the necessary education and tools to work at or above their education and
training level. This patient-centered approach also helps the oncology team as the APP's are no
longer asked to conduct this teaching and can increase patient volumes.
The nurse-led pre-treatment training increases patient's knowledge before undertaking a
stressful and potentially unpleasant chapter in their lives. The information gained allows the
patient to self-manage side effects proactively and gives them a sense of control when life seems
uncontrollable.
Long-term effects of the use of this educational information and toolkit are that it is
easily modified to be utilized in a variety of outpatient oncology clinics throughout the larger
system, and new staff may be educated in its use. I have participated in several meetings with
clinical educators aligned with outpatient and inpatient care at Stanford Healthcare to discuss this
QI project and its contents and how it may be utilized in other areas at Stanford. This is an
ongoing effort that I intend to be aligned with to offer my support as needed. It is also anticipated
that clinic leadership will ensure ongoing use and sustainability of this process as positive results

45
have shown improved quality of care, increased nurse coordinator satisfaction and engagement,
along ease of transferability to a global audience.
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Section VI: Funding
Funding for the cost of materials, flyers, printing, and toolkit information came from
Stanford Oncology Women's Cancer SQIMM funds. This DNP candidate's work consisted of
voluntary use of time to develop the toolkit content, implement the process, and analyze the
findings. All the time spent on the project was approved and encouraged by the student's clinic
manager. I received no additional or outside funding.
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Section VIII: Appendices

Appendix A: IRB and Statement of Determination

DNP Statement of Non-Research Determination Form: Laura Oka
Title of Project: Improving Nurse-Led Oncology Pre-Treatment Education
Brief Description of Project: The oncology nurse coordinator's role in a large academic
outpatient oncology clinic is continually being modified to assist the patient care team
better to improve patient education. This education consists of pre-treatment care planning
and conducting a clinic visit to educate the chemotherapy-naive patient before
treatment. Historically, this education has been given by the Advanced Practice
Professional (APP). As nurse coordinators are now taking on a more prominent role in
patient education, a gap has been identified about how effective the nurse is in conducting
this educational visit and having access to standardized references to utilize during the
clinic visit.
A pilot had been proposed and is supported by leadership to evaluate the effectiveness of
instituting a clinic-specific reference toolkit to improve the Registered Nurse (RN) comfort
level of conducting the visit.
A) Aim Statement: By January 2021, develop, implement and evaluate a pre-treatment
toolkit to be utilized for newly diagnosed cancer patients at Stanford Healthcare outpatient
oncology clinics.
B) Description of Intervention: This Doctor of Nursing (DNP) change of practice project
will have several phases.
The first phase will involve the DNP student working with key stakeholders to develop the
clinic-specific evidence-based reference tools to be utilized during the pilot. As the
facilitator in this project, the DNP student will build a compelling business case based on
peer-reviewed literature presented to leadership to gain approval for the pilot project.
The second phase will involve working with the clinic RN's to engage and elicit feedback
via an anonymous survey to improve the toolkit's effectiveness and before the pilot's
implementation process and launch.
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The third phase will be the pilot's actual launch and gaining feedback related to the toolkit's
flow. A post-survey will be conducted to assess the RN's comfort and confidence in
independently conducting this educational pre-treatment clinic visit with the toolkit's
assistance.
Identified stakeholders at a clinic-based council meeting will anonymously provide
feedback by completing a brief 5-point Likert-type scale to assist in and give feedback on
the proposed reference tool content, organization, appropriateness, and ease of use help in
tool development.
All RN's who utilized the new process and its content will then be asked to complete a
post-pilot 5-point Likert-type scale survey related to their comfort level and confidence in
conducting the pre-treatment visit, utilizing the toolkit, and rate this perceived experience.
Results will be measured by comparing pre-and post-intervention mean scores.

C) How will this intervention change practice? By implementing an evidence-based
reference toolkit, it is anticipated that improvements will be made to increase the nurse
coordinator's effectiveness to work at the highest level of their education. This will then
allow the APP to focus on seeing patients independently in-clinic appointments.
D) Outcome measurements:
1. RN knowledge base related to imperative information necessary to educate the
patient before the first treatment will increase by 20 %.
2. RN's ability to utilize specific information included in the nurse pre-treatment
toolkit will increase by 20 %.
3. RN knowledge base related to how the pre-treatment educational visit will be
documented will increase by 20 %.
4. RN knowledge base related to how a patient is scheduled for a nurse pre-treatment
patient educational visit will increase by 20 %.
To qualify as an Evidence-based Change in Practice Project, rather than a Research Project, the
criteria outlined in federal guidelines will be used:
(http://answers.hhs.gov/ohrp/categories/1569)
This project meets the guidelines for an Evidence-based Change in Practice Project as
outlined in the Project Checklist (attached). The student may proceed with implementation.
This project involves research with human subjects and must be submitted for IRB approval
before the project activity can commence.
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Appendix B: Letter of Support
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Appendix C: Evidence Evaluation Table

Citation

Evidence Type

Jivraj et
al.
(2018)

Quality
Improvement

Mann
(2011)

Quality
Improvement

FeeMixed method
Schroeder Quality
et al.
Improvement
(2013)

Aranda et
al.
(2012)

A parallel groupprospective
randomized,
controlled trial

Sample
Size &
Setting
N = 37/
Canadian
outpatient
clinic
N = 72/
Outpatient
clinic in
Northern
Alabama
N =81/
Large
academic
outpatient
cancer
center
N =192/
Large
cancer
hospital in
Melbourne,
Australia

Study Findings

Limitations

Evidence &
Quality Level

Individual pre-treatment
education is more
valuable than a broad
group class
Assessing individual
patient needs along with
effective education
ensures a more positive
patient experience
Facilitated discussion by
an oncology nurse
increases patient
knowledge r/t
chemotherapy side effect
management and self-care
strategies to manage

Metrics were not
kept/Small
sample size.

Current prechemotherapy
preparation is suboptimal,
and not much research has
studied how this affects
patient distress regarding
treatment-related
concerns. A nurse-led
prechemotherapy
educational intervention
shows promise to improve
these concerns and
physical/psychological
outcomes

Limited sample
Level 1,
size. The study
Quality B
was undertaken at
a single specialist
cancer center and
studied a limited
population

Level V,
Quality B

Small sample size Level V,
Quality B

Two limitations
Level V,
noted: the use of
Quality B
a convenience
sample and
questionnaire was
not validated
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Dalby et
al.
(2013)

Process
improvement
project

N=53/
Prominent
Cancer
Institute in
Boston,
MA

Standardizing
chemotherapy education
improves the patient's
understanding of their
upcoming treatments
using standardized
checklists to provide a
teaching framework.
Calendars are also helpful
and should be
implemented into practice

Wagner
et al.
(2018)

Cluster
randomized
control trial

N=251/
Several
oncology
clinics
within a
large center
in the
Pacific
Northwest

Nurse navigator support
for patients with early
cancer significantly
improved the patient
experience and reduced
care problems but did not
affect the quality of life

Munoz et
al.
(2018)

Retrospective
study/Literature
review

N= 60/
Large
community
medical
center in
Fresno, CA

The inclusion of an
oncology nurse navigator
results in a shorter time
lapse between diagnosis
and commencement of
treatment

The teaching
session's timing
was not
standardized
when the session
was conducted
from 2 weeks
before the first
treatment or the
same day. This
may have
influenced the
measured
outcomes
Limitations
included the
atypicality of the
setting, lack of
baseline data for
the questions,
random
assignment of
physicians rather
than patients, and
limited sample
size
Multiple
independent
variables such as
patient
socioeconomic
status,
availability of
resources,
medical group,
and existing
comorbidities can
influence
outcomes. The
inclusion of the
multidisciplinary
tumor board may
have influenced
the study results
as well

Level V
Quality B

Level 1
Quality B

Level V
Quality B
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Apor et
al. (2017)

Comparative
study through
survey data

N=196/
A
prominent
academic
institution
in Boston,
MA

The patient's
understanding of
treatment schedule,
potential adverse effects,
and antiemetic medication
regimen showed
significant increases after
undergoing a teaching
session by an oncology
nurse before commencing
the first treatment

The survey
instrument was
not previously
validated.
Information
related to the
patient's cancer
staging was not
utilized as some
stages are not
curable and
palliative in
intent to treat

Level V
Quality B
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Appendix D: Gap Analysis

Strategic Objective

Current Status

Deficiency

Identifying information clinic, NC deems
most valuable to know to give the pretreatment teaching session.

No feedback initiative has ever
been completed to identify
knowledge gaps among NC to
identify education gaps related
to independently conducting
the pre-treatment educational
visit.
No initiative has ever been
undertaken to develop specific,
universal teaching materials
for use in the clinic to teach
patients who are starting
chemotherapy treatments.
The majority of NC and
support personnel are not
aware of supplemental clinic
recourses available to conduct
a pre-teaching session.

Knowledge/comfort levels related
to NC's conducting a pre-treatment
educational visit vary by
individuals as some nurses have
some experience with this.

Develop clinic-specific reference sheets to
capture and identify pertinent information.

Improve communication of availability of
clinic toolkit resources. Assign
responsibility of supportive personal to
make sure the toolkit is compiled and
readily available.

Develop and implement a
No sustainability/
sustainability/responsibility plan for future responsibility plan exists for
resource management of toolkit recourses. resource management
currently.

Action Plan

Communicate with
relevant stakeholders to
discuss and determine
what information would
be deemed valuable and
included in the teaching
toolkit.
No specific reference sheets
Collaborate with clinic
currently exist for utilization by the stakeholders to develop
NC to conduct a teaching session.
evidence-based clinicSome educational information
specific reference sheets
exists related to APP teaching but is to be utilized in the
not consistent.
teaching toolkit.
Without specific, universal teaching Promote the use of the
materials, the NC is not
toolkit supplemental
consistently teaching the new
information availability
chemotherapy treatment patients.
and location of such
This may lead to patients not
information in daily clinic
receiving effective pre-treatment
huddles.
education.
Without the necessary toolkit
NC and clinic leadership
information available, the NC will
review and revise clinicneed to compile and print data.
specific resources sheets
Knowledge needs to be up to date
annually to change and
and modified as required.
update as needed.
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Appendix E: Gantt Chart
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Appendix F: Work Breakdown Structure

Improving Nurse Led Chemotherapy Teaching

Define

Gap Analysis
EPB Practice
change

Identify PICO
question

Literature review
and appraisal

Cost analysis, and
plan proposal

Plan

Develop
deliverables and
milestones

Discuss with
stakeholders and
decide which info
to use

Compile toolkit
information
Formulate Likert
scale survey
questions for
pre/post test

Launch

Breakdown of project
workflow

Administer preintervention survey to
nurses

Introduce and educate
nurses on toolkit
through 1:1 and group
meetings as needed

Sit in on real time
chemotherapy teaching
session with nurses.
Obtain and give feedback

Manage

PDSA’s completed and
modify toolkit or nurse
education as necessary

Administer postimplementation survey to
nurses

Closeout

Outcomes evaluation
and present data to
stakeholders

Sustainability plan:
Assign admin to ensure
toolkits are available

Final project writeup

DNP presentation
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Appendix G: Responsibility Matrix
Name

Role

Responsibility

DNP Student

Project manager/facilitator

Facilitate development, implementation,
rollout, progression, data analysis, and
closeout

Unit leadership

Promoter

Grant initial approval for the plan.
Provide feedback for process flow issues
and guidance throughout

Clinic-based Nurse Coordinators (NC’s)

Facilitator and Collaborators

Tool development, rollout, and project
progression at the unit level

Unit Clinical Administrative/Medical
Assistants (CAA’s)

Facilitator and Distributor

Tool disbursement
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Appendix H: Communication Matrix

Information

Target Audience

When

Method of

Responsible

Communication
Project Proposal

Nurse Manager and lead
APP

Project overview& tool
development plan

Clinic nurses, APP's
MD's, administrators,
and medical assistants

Project overview &
rollout plan

Clinic nurses,
administrators, and
medical assistants
Clinic nurses, APP's

Pre-implementation
survey

8/2019

9/2019-12/2019

7/2019

12/2019

Project pilot start,
progression, up
dates & close-out

All key stakeholders

1/2020-6/2020

Post-implementation
survey

Clinic nurses, APP's

7/2020

Communication of
project results & final
presentation

All key stakeholders

12/2021

In-person meeting

DNP student

In-person presentation
at monthly CCP
meeting

DNP student

In-person during daily
AM huddles for two
weeks before rollout
Email to target audience
and survey to be placed
in each nurse's mailbox
In-person monthly CCP
meeting, a weekly
check-in with unit
leadership
Email to target audience
and survey to be placed
in each nurse's mailbox
CCP monthly meeting

DNP student

DNP student

DNP student

DNP student

DNP student
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Appendix I: SWOT Analysis

Strengths
Strong executive leadership and management level support
Large academic facility utilizing evidence-based protocols and
interventions
Nurse advocacy is inherent to the role of the nurse coordinator
Multiple studies in the literature related to process improvement
changes of this type

Opportunities

Weaknesses
Limited research-related (cohort studies, RCTs, evidence summaries)
articles as the subject matter did not yield literature of this type
Lack of administrative support personnel to offload non-clinical
workflow
Poor rapport with some providers between the nurse coordinator and
MD/APP
Decreased engagement due to high acuity/stress within the clinic
Low staff morale/high turnover

Threats

Promote the role of nurse coordinator as an integral asset to the
team-based care that Stanford Healthcare gives its patients.

Decreasing the role of NC in the oncology clinics at Stanford Healthcare
due to monetary restraints

This comprehensive individualized education may also have an
impact on patient satisfaction scores and will benefit the
organization.

Possibility of leadership modifying the team-based role the NC
currently plays into more of a triage nurse who is less involved in point
of care patient teaching
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Appendix J: Budget
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Appendix K: Expected Revenue

*Cost per provider for outpatient visit for evaluation and treatment of a new patient with an RVU of 5.
**Estimated increase in annual revenue of seeing additional patients (Days per year (240 days/year)).
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Appendix L: Data Collection Tools

Nurse-led Pre-Intervention Education Experience Survey
1. I know what is expected of me in conducting an independent nurse pre-treatment patient
educational visit.
⃞ Strongly agree

⃞ Agree

⃞ Disagree

⃞ Strongly Disagree

2. I know what specific information should be included in the nurse pre-treatment patient
educational visit.
⃞ Strongly agree

⃞ Agree

⃞ Disagree

⃞ Strongly Disagree

3. I understand the process related to how a patient is scheduled for the nurse pre-treatment
patient educational visit.
⃞ Strongly agree

⃞ Agree

⃞ Disagree

⃞ Strongly Disagree

4. I understand the process of how to document the information from the nurse pretreatment patient educational visit in EPIC.
⃞ Strongly agree

⃞ Agree

⃞ Disagree

⃞ Strongly Disagree

How do you feel the education and use of the nurse-led pre-treatment patient education will
likely change your practice?

How do you feel your contribution as a team member in the nurse coordinator role is
highlighted or not highlighted by having the nurse coordinator conduct the nurse-led pretreatment education clinic visit?
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Nurse-led Post-Intervention Education Experience Survey
1. I know what is expected of me in conducting an independent nurse pre-treatment patient
educational visit.
⃞ Strongly agree

⃞ Agree

⃞ Disagree

⃞ Strongly Disagree

2. I know what specific information should be included in the nurse pre-treatment patient
educational visit.
⃞ Strongly agree

⃞ Agree

⃞ Disagree

⃞ Strongly Disagree

3. I understand the process related to how a patient is scheduled for the nurse pre-treatment
patient educational visit.
⃞ Strongly agree

⃞ Agree

⃞ Disagree

⃞ Strongly Disagree

4. I understand the process of how to document the information from the nurse pretreatment patient educational visit in EPIC.
⃞ Strongly agree

⃞ Agree

⃞ Disagree

⃞ Strongly Disagree

How do you feel the education and use of the nurse-led pre-treatment patient education will
likely change your practice?

How do you feel your contribution as a team member in the nurse coordinator role is
highlighted or not highlighted by having the nurse coordinator conduct the nurse-led pretreatment education clinic visit?
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Appendix M: Pre-and Post-Survey Charts

Pre Questionnaire
4.00
3.00
2.00
1.00
0.00
I know what is expected of
me in conducting an
independent nurse pretreatment pati ent
educational visit.

I know what specific
information should be
included in the nurse pretreatment pati ent
educational visit.

I understand the process
I understand the process of
related to how a patient is
how to document the
scheduled for the nurse pre- information from the nurse
treatment pati ent
pre-treatment patient
educational visit.
educational visit in EPIC.

1 = Strongly Disagree 2 = Disagree 3 = Agree 4 = Strongly Agree

Post Questionnaire
4.00
3.00
2.00
1.00
0.00
I know what is expected of
me in conducting an
independent nurse pretreatment pati ent
educational visit.

I know what specific
information should be
included in the nurse pretreatment pati ent
educational visit.

I understand the process
I understand the process of
related to how a patient is
how to document the
scheduled for the nurse pre- information from the nurse
treatment pati ent
pre-treatment patient
educational visit.
educational visit in EPIC.

1 = Strongly Disagree 2 = Disagree 3 = Agree 4 = Strongly Agree
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Appendix N: Focus Group Information
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Appendix O: Pre-Treatment Nurse Checklist

Nurse Coordinator Pre-Treatment Educational Visit Checklist
Intro:
• Introduce yourself and your role, including working together as a team (MD, APP,
Fellow, Resident, CAA, and MA).
Need for Systemic treatment:
• Cancer treatments may consist of surgery to remove the tumor tissue, systemic
therapies such as IV Chemotherapy treatments, Radiation, and oral anti-estrogen
inhibitors. These treatments are recommended to give you the best chance of killing
any cancer cells locally or those potentially circulating in your body
How does Chemotherapy work?
•

Typically, cells live, grow and die predictably. Cancer occurs when specific cells in
the body keep dividing and forming more cells without the ability to stop this process.
Chemotherapy protocols involve destroying cancer cells by keeping the cells from
further multiplying. Unfortunately, in the process of undergoing chemotherapy
protocols, healthy cells can also be affected, especially those that naturally should
divide quickly.

•

Chemotherapy drugs that kill cancer cells only when they are dividing are called cellcycle specific. Chemotherapy drugs that kill cancer cells when they are at rest are
called cell-cycle non-specific. The scheduling of chemotherapy is set based on the
type of cells, the rate at which they divide, and the time at which a given drug is
likely to be effective. Therefore, chemotherapy is typically given in cycles.

Why you may experience common side effects:
•

Chemotherapy is most effective at killing cells that are rapidly dividing.
Unfortunately, chemotherapy does not know the difference between cancer cells and
normal cells. The "normal" cells will grow back and be healthy, but, in the meantime,
side effects occur. The "normal" cells most affected by chemotherapy are blood cells,
cells in the mouth, stomach, bowel, and hair follicles, resulting in low blood counts,
mouth sores, nausea, diarrhea, and/or hair loss. Different drugs may affect other parts
of the body. Fortunately, we have very effective medications to help manage these
unpleasant side effects.

Specific Treatment Plan:
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Your Doctor has chosen specific chemotherapy drugs based on
• Research: specific protocols based on cancer type, stage, and other specifics.
• Response rates: established through years of research and is how a type or stage
of cancer will respond to a particular drug.
• The health of the patient; due to the toxicities of chemotherapy, risk vs. benefit
must be taken into consideration when deciding treatments.
•

(Go over specific common agents' side effects related to the patient’s
chemotherapy. Print out the chemotherapy sheets from Chemocare.com to
include in the toolkit)

Adjuvant vs Neoadjuvant treatment:
•
•

Adjuvant treatments consist of having surgery followed by chemotherapy and
then radiation if indicated.
Neo-adjuvant consists of having chemotherapy up-front to help shrink the tumor's
size and assess response to treatment. Surgery is then completed, followed by
radiation if indicated.

Three main agents:
-ACT=Adriamycin (Doxorubicin) & Cytoxan (Cyclophosphamide), which will be given
Q3 weeks X 4 cycles
Followed by:
-Taxol (Paclitaxel) given weekly X 12 cycles or DD Q 3 weeks X 4 cycles
-TC= Taxotere (Docetaxel) and Cytoxan (Cyclophosphamide), which will be given every
three weeks X 4-6 cycles
-TCHP= Taxotere (Docetaxel), Carboplatin (Paraplatin), Herceptin (Trastuzumab), and
Perjeta (Pertuzumab) given every three weeks X 4-6 cycles with Herceptin and (possibly
Perjeta) to complete one year of treatment.
Nadar Affects Blood Cell and Platelet Counts:
•

When chemotherapy is given, it not only affects the rapidly dividing cancer cell,
but it also involves some of the normal cells of the body. These effects mainly
occur on normal cells that divide quickly, such as the hair, the lining of the mouth,
the cells lining the intestinal tract, and the blood cells (white and red blood cells
and platelets).

•

The nadir time is usually about 7-10 days after treatment, although this may vary
depending on the drugs given. During the nadir time, the concern is that the
body's first line of defense against infection, white blood cells (WBC), is low,
leaving a person more susceptible to disease. The next dose of chemotherapy is
given only after a person's blood counts have left the nadir and recovered to a safe
level.
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•

Neulasta or (Pegfilgrastim) is a colony-stimulating factor, meaning it is given 24
hours after receiving chemotherapy to help stimulate the growth of “health” WBC
in the bone marrow. We now have a device called Onpro, an on-body injector
placed on your skin, and self-inject a preprogrammed amount of medication while
you are at home. Your infusion nurse will show you a video and explain how it
works at your first treatment.

•

This medication sometimes causes body ache and bone pain. The pain may be
alleviated by taking Claritin daily in the morning of days 2-6. You may also use
Tylenol/Motrin as needed for pain.

Medi Port, Echo, labs, home meds:
•

An implanted port is sometimes recommended before starting specific
chemotherapy treatments due to potential injection site reactions and treatments'
longevity.

•

An Echocardiogram (ECHO) is an ultrasound test of your heart to evaluate how
well the left ventricle functions. It is usually recommended for Her2 directed
treatments such as Herceptin and Perjeta, baseline and every three months
throughout treatment. It is also recommended to have a baseline ECHO before
starting Doxorubicin.

•

We will have you obtain labs before each treatment to assess how your body
reacts to the chemotherapy. Walk walk-in labs do not require an appointment, and
our infusion schedulers will schedule port labs.

•

At-home medications will be sent to your pharmacy of choice, and we will go
over the recommended schedule of how to take the best to prevent symptoms of
nausea/vomiting after each treatment. Please make sure you pick them up before
starting treatment.

What happens in the infusion center?
•

Your team of providers at the infusion center are highly trained oncology nurses
and are available to answer many of your questions. They are also trained to help
manage chemotherapy reactions/allergies if they occur.

•

It is advised to wear comfortable clothes to the treatment. Eat a light breakfast and
bring some snacks/lunch with you as you may be there for many hours. You may
also bring your computer, iPad, earphones, or a good book with you. The staff
will do their best to make sure you are comfortable and try to decrease any
distractions.
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•

The sequence of treatments will be IV fluids and pre-meds followed by
chemotherapy and then more hydration.

Side Effects: Expected vs. Serious ** Discuss with your care team if you have these
symptoms.
•
•
•
•
•
•
•
•
•
•
•
•

Fatigue**
Body ache
Muscle ache
Lack of appetite**
Nausea
Mouth Sores**
Constipation/Diarrhea
Decreased blood counts (anemia/depressed immune system/risk of bleeding)
Hair loss
Allergic symptoms (itching/hives/swelling are the most common) **
Numbness/tingling in the hands and feet (Neuropathy)**
Chest pain/shortness of breath/lower extremity swelling**

Nausea/Vomiting:
The best way to treat nausea/vomiting is to prevent it! These are the recommended medications to
take at home after your treatment (see recommended at-home symptom management medication
sheet)
•
•
•

Zofran
Compazine
Ativan

•

Decadron if receiving Taxotere: Some treatment medications such as Docetaxel
require you to take three days of a steroid called Decadron at each cycle's start. The
use of this steroid is to decrease the side effect of a treatment reaction and have the
added benefit of helping reduce nausea related side effects

•

*If you are taking the at-home medications as recommended and are still having
N/V or are unable to keep foods or fluids down, please notify us as you may need
to come in to get hydration or IV anti-nausea medications in the ITA.

Constipation:
Some anti-nausea medication, as well as chemotherapy, may cause constipation. You may find it
helpful to use a mild laxative such as OTC Colace to help prevent this.
•

Colace
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• Senokot
• MiraLAX
• Smooth Move Tea
Other more natural options that may work for you:
• Drink 2-3 litters of fluid/day
• Try to get moderate exercise 20-30 minutes/day
• Limit alcohol to 1 glass/day
• Try ground fresh flax seeds over your cereal.
• Fresh celery sticks
• Prune juice or pureed prune baby food
Diarrhea
You may find that you alternate between constipation and diarrhea during chemotherapy. If you
have diarrhea:
•
•
•

BRAT diet: bananas/rice/apple sauce/ toast
Increase fluid intake
OTC Imodium as directed

Mouth Care:
If you have mild soreness or mouth redness:
• Brush with a soft toothbrush 4X/day
• Apply a lip moisturizer
• Avoid consuming scalding hot liquids
• Arrange to have a checkup with your dentist before starting treatments.
-1 Tablespoon of baking soda and 1 Tablespoon of salt in 2 pints of water. Swish and gargle 4
four times/day
-Avoid over the counter mouth rinses like Listerine or Scope as they have alcohol in them
-Biotin Mouthwash three times/day (to help prevent mouth sores)
-Stomatitis cocktail (prescription numbing mouthwash if you develop open mouth sores)
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Low White Blood Cell Count or symptoms of infection/sickness
If you develop a temperature >100.4, F or 38 C, you must notify us promptly. Monday thru
Friday, during regular hours, you may call us at 650-498-6004. The call center will send us an
urgent page to call you back and get more information. After hours, weekends, evenings, or
holidays you need to call the after-hours line any time at 650-723-6661 to discuss with a triage
RN or MD.
Fevers can be a sign of infection, and if your WBC is low, it is difficult for your body to fight
infection. You may be asked to come in to get lab work done and may be asked to start taking
antibiotics.
Miscellaneous Info:
•
•
•

Drink at least 2-3 liters of water/day (8-10 glasses or 2-3 quarts) every day, unless
directed otherwise by your doctor. Fluid examples may be water, juice, sports
drinks, broth, soup, popsicles, and jello
Avoid eating raw fish
Handwashing is the number one defense to fight off infection.

When should I call my healthcare team?
•

A fever of 100.5 F or greater

Supportive Care program
•
•

#650-725-9456
www.cancer.net American Society of Clinical Oncology (ASC). This is an evidencebased website containing evidence-based information.

“The best cancer care starts with the best cancer information.”
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Appendix P: Pre-Planning Tool

Pre-Planning Tool
Patient_____________________

Physician_________________

MR_______________

Diagnosis___________________

PLAN
Regimen____________________

Cycles____________________

Surgery_____________________

Date_____________________

XRT________________________

Date_____________________

SCANS

Start Date_________

PRE-PLANNING

CT CAP _________

Beacon Plan entered ________
Authorization OK’d ________

Bone Scan _______

Port__________________

PET ________

ECHO_________________

Outside Path review ________

Labs__________________

Outside Scan Review ________

Home Meds____________

Oncotype _________

Pharmacy______________
Chemo teach___________
1st Appointment Scheduled _____________

Issues:

4/3/2020
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Appendix Q: Chemo Fact Sheet

Stanford Women’s Cancer Center
Breast Oncology Chemotherapy Fact Sheet
A Guide to Cancer Infusion Therapy
Your oncology team will review the schedule for your
chemotherapy, depending on your treatment plan.
Schedules may change for many reasons. We ask that you be as flexible as possible with
treatment days and times. Please notify the scheduler in advance of your preference in location
and time (we will do our best with your request, but unfortunately, we can’t guarantee this will
happen). Unexpected events about your treatment and/or the treatments of other patients can
often cause delays. You may have less stress if you do not make other commitments on the day of
your infusion appointment.
Your chemotherapy will be given through an IV (intravenously). The treatment is provided in the
ITA (Infusion Treatment Area), located at one of our 3 locations.
Stanford Cancer Center Infusion Treatment Locations
875 Blake Wilbur Drive
450 Broadway Street
2589 Samaritan Drive
2nd Floor
Pavilion B35, 3rd Floor
4th Floor
Palo Alto, CA 94304
Redwood City, CA 94063
San Jose, CA 95124
Phone: 650-725-1860
Phone: 650-724-6140
Phone: 408-426-4900
Tests before treatment
You may need some tests before starting your treatment. These help the doctors make sure
you’re well enough to have your treatment. They will usually include blood tests and maybe
urine or heart tests. Sometimes, you may also need to have x-rays or scans before treatment
starts. Before each treatment cycle, it is normal to have a blood test and see the doctor or nurse.
This may be on the day of your treatment or a day or two before it. They will check your blood
results and ask you how you have felt since your last treatment.
Along with the chemotherapy, you will be receiving fluids to hydrate you and medications to
help prevent nausea and sometimes allergy symptoms (ex. itching). If your IV access is difficult
or painful for you, ask us about a central venous port (a more permanent IV access placed under
the skin to be used for blood draws and chemotherapy). The port can be removed at the end of
your treatments.
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Common Side Effects of Chemotherapy
** Discuss with your care team if you have these symptoms.
• Fatigue**
• Body ache
• Muscle ache
• Lack of appetite**
• Nausea
• Mouth sores
• Constipation/Diarrhea
• Decreased blood counts (anemia/depressed immune system/risk of bleeding)
• Hair loss
• Allergic symptoms (itching/hives/swelling are the most common) **
• Numbness/tingling in the hands and feet **
• Chest pain/Shortness of breath/lower extremity swelling**
Not all side effects are experienced by every patient. Every chemotherapy drug has a different
set of side effects. Depending on your treatment plan, we will let you know which side effects to
be concerned about most.
Below will review some techniques to manage the common symptoms
Nausea/Vomiting:
This symptom is usually well controlled with the proper medications. We rarely have patients
who have vomiting after treatment. More commonly, patients will describe mild nausea or lack
of appetite for a few days after treatment. The best way to treat nausea is to prevent it! We will
give you medications during the chemotherapy and ask you to take some medicines at home to
help prevent the onset of nausea. Below are the medications you should take with your
treatment.
Start these medications as advised. Take them on a schedule as below during the hours you are
awake. Sometimes these medications can need prior authorization from your insurance before
you can get it- your pharmacy will let you know if you need this, and our team will help you get
it authorized. Not all chemotherapy will require a nausea regimen. We will tell you what we
recommend you take.
⎕ Zofran (ondansetron) 8mg - Start the morning after your chemo infusion. Take one tablet
every 8 hours for 2 to 3 days after treatment.
⎕ Ativan (lorazepam) 1mg - Start the evening of your chemo infusion. Take one tablet at
bedtime for 2 – 3 days starting the infusion day to help you sleep and prevent nausea/vomiting.
⎕ Compazine (prochlorperazine) - 10mg Take one tablet every 6-8 hours as needed for nausea if
Zofran is not effective.

If your chemotherapy is particularly more nauseating or we find that the above medications are
not quite enough to control your nausea, we may add:
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⎕ Emend (aprepitant) 150mg IV. We can add this to your premedication through the IV.
⎕ Aloxi IV 0.25mg/5ml – infused before chemotherapy.
⎕ Decadron 4mg- take one tablet twice daily for two days after chemotherapy.
We can make other changes to help control nausea if needed, such as additional hydration in the
Infusion Treatment Area (ITA).

Constipation
Chemotherapy, as well as the medications we use for pain or nausea, can cause constipation. We
recommend that your start taking a mild laxative the day of chemotherapy to help prevent this.
Please use one of the following:

Please mark the medications that are appropriate for your patient:
⎕ Colace 100mg (docusate sodium) Take 1-2 tablets twice daily (stool softener)
⎕ Senokot Take 1-2 tablets twice daily for constipation
⎕ MiraLAX 17g Mix with water or juice and drink daily (this is a suitable medication for daily
maintenance, it does not work well once you are constipated)
⎕ Smooth move tea (gentle) for those who are more sensitive to laxatives. Available at Whole
Foods or other natural grocers.
Other more natural options that may or may work for you:
• Drink 2-3 liters of fluid per day (especially if you take a fiber supplement or have a highfiber diet)
• Try to get moderate exercise 20-30 minutes per day
• Limit alcohol to 1 glass per night
• Try ground fresh flax seeds over your cereal.
• Try fresh celery sticks
• Try prune juice or pureed prune baby food (still a great option after all these years)

Diarrhea
Some patients will alternate between constipation and diarrhea during the chemotherapy. If you
have diarrhea:
⎕ BRAT diet: bananas/rice/apple sauce/toast
⎕ Drink plenty of fluids. Avoid sugary or processed foods that can exacerbate diarrhea.
⎕ Imodium Over the counter, take as directed
Mouth Care
If you have mild soreness or mouth redness:
• Brush with a soft toothbrush 4x/day and floss daily
• Apply a lip moisturizer
• Avoid consuming scalding liquids
• Arrange to have a checkup with your dentist before starting treatment
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⎕ 1 Tablespoon of baking soda and one tablespoon of salt in two pints of water. Swish and
gargle 4
times a day.
⎕ Avoid over the counter mouth rinses like Listerine or Scope
⎕ Biotin Mouthwash three times daily (to help prevent mouth sores)
⎕ Stomatitis cocktail (prescription numbing mouthwash if you develop open mouth sores)
Allergic/Hypersensitivity Reactions
These reactions are more common with certain chemotherapy medications than others. They
usually occur during the infusion. Symptoms include itching, flushing, hives, shortness of
breath, chest tightness, and low blood pressure. The symptoms typically resolve with Benadryl
and sometimes from steroid medication. Rarely are the reactions more severe.
If you have a mild reaction, we may ask you to take allergy medication before chemotherapy and
possibly a low-dose steroid called Decadron.

Low White Blood Cell Count
Your white blood cells are your infection-fighting cells (immune system). You may be at risk
for this, depending on the type of treatment you are receiving. The more chemotherapy you
receive, the more at risk your bone marrow is for low white blood cell counts.
White cells typically go down to their lowest approximately 7-10 days after chemotherapy and
then start to recover. This is called the Nadir.
If you ever have a fever at home >100.5 F or 38 C, you need to call our office during regular
business hours at 650 498-6004 or after hours: Please call 650-723-6661
Fevers can be a sign of infection, and if your white count is low, it is difficult for your body to
fight infection. We will likely ask you to come in to have your blood counts checked, and you
may need antibiotics.
If your blood counts are getting too low before each treatment, we may use a medication to help
stimulate your bone marrow to make more white blood cells.
Neulasta (pegfilgrastim) 6mg subcutaneous ONE time the day after chemotherapy.
This is a LONG-ACTING form of Neupogen.
It is given once after chemotherapy.
We can give it to you in the ITA 24 hours after chemotherapy. You may also receive this
medication in the form of a patch that self-injects 24 hours after chemotherapy called Onpro.
Your infusion nurse (chemotherapy nurse) will again go over how to manage the patch.
You should not receive chemotherapy again for at least 14 days after this injection.
This medication can cause body ache and bone pain (back/chest/long bones). The pain can be
alleviated by taking Claritin daily in the morning of days 2-6 each cycle. You may also use
Tylenol/Motrin as needed for pain.
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Muscle and Joint aches
Muscle aches can be caused by chemotherapy. They typically start the day after treatment and
can last for 2-3 days. Paclitaxel is one of the chemotherapy drugs we give that can cause this.
You can take anti-inflammatory drugs such as Motrin/Ibuprofen or Tylenol to help with the pain.
Warm packs/ warm baths/and massages are also good options. Not everyone will experience
these symptoms, and for some, they may be very mild.
Miscellaneous info:
• Drink at least 2-3 liters (8-10 glasses or 2-3 quarts) every day unless directed otherwise
by your doctor. Examples of fluids are water, juice, sports drinks, broth, popsicles, and
jello.
• Avoid eating any raw fish, raw eggs, or raw meat. It is okay to eat fruits and vegetables.
Make sure to wash them well.
• Hand washing is the number one defense to fight infection. Please be sure to wash your
hands frequently.
When should I call my healthcare team?
•
•
•
•
•
•
•
•
•
•

A fever of 100.5° Fahrenheit, or greater.
Bleeding or unusual bruising.
Burning and/or pain when urinating.
Constipation (no bowel movement in 2-3 days).
Diarrhea (loose, watery stools) - four or more watery stools in 24 hours.
Nausea, vomiting, or if you cannot keep down any liquids.
Your current medications do not control pain.
Redness, pain, sores, or a white coating in your mouth.
Shaking and chills.
Unusual cough, sore throat, lung congestion, or shortness of breath.

You may also get additional instructions about when to call your healthcare team.
We are here to help support you and allow you to complete the treatment safely and as
comfortably as possible. Please stay in close touch with us (my health online is an easy way to
ask quick questions or let us know how you are doing) to help manage symptoms and do our best
to maintain your quality of life through this journey.
Depending on our treatment plan and the type of work you do, some patients will continue to
work on a part-time basis through treatment. If you choose to take time off, we can have our
administrative coordinator contact you to help with forms and letters.
Important Phone Numbers
If you have a question or concern: Please call 650-498-6004
•

Leave a message with the phone operator, and you will receive a call back from our nurse
coordinator the same day
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•

If your question is determined to be urgent, you will be transferred to a triage nurse who
will contact the appropriate provider (MD/NP) to answer your concern

If you have a non-urgent question for your doctor or nurse practitioner:
• You may communicate with them over “My Health.”
• “My Health” is a secure email system within Stanford that we can use to share important
information from your health record with you
• Ask our staff how you can sign up for “My Health.”
• Please be aware we do not monitor this portal on evenings, weekends, or holidays
If you are experiencing a medical problem after hours: Please call 650-723-6661
• If this is a life-threatening condition, call 911
• Do not send a my-health message during after-hours as we do not monitor this portal.
• Ask to speak with the breast oncology on-call staff
• Someone is always available to assist you
• Appointments: Please call 650-498-6004
• For an appointment in the ITA (infusion treatment area)
• After your visit, if you need to schedule a radiology test: Please call 650-723-6855
• If you need to obtain copies of medical records: Please call 650-723-5721
• If you need to schedule an ECHO test for your heart: Please call 650-723-7406
Cancer Supportive Care Program
Our supportive cancer care program offers:
•
•
•
•
•

Educational classes and workshops such as lymphedema, chemotherapy, and radiation
classes
1:1 exercise consultation with cancer care specialist offering various yoga, palates,
Taiichi, dance, and exercise classes
Mindfulness meditation
Support groups
Healing touch, wig band, skincare, and scarf tying class

Please call 650-725-9456 to get more information or go to the supportive care website:
https://standordhealthcare.org/for-patients-visitors/cancer-supportive-care-program-html

www.Cancer.net for Doctor-Approved Patient Information from American Society of
Clinical Oncology (ASCO)
“The best cancer care starts with the best cancer information.”
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Appendix R: At Home Medication Management

Patient Name: ____________________________ M RN__________________ T reatment_____________ _____________________________

Recommended at home symptom management medications
Drug Name

Day Before
Chemo

Day of
Chemo

Day 2 after Chemo

Day 3 after Chemo

(take 2-3 times a day)
8 am
4 pm
10 pm

(take 2-3 times a day)
8 am
4 pm
10 pm

As needed
every 6-8
hours

As needed every 6-8
hours

As needed every 6-8
hours

Side effects are sleepiness
and twitching or anxious
feeling

At bedtime

At bedtime

At bedtime as needed

At bedtime as needed

Side effects are sleepiness
and amnesia

2 tabs 2
times per
day
(Breakfast
and Lunch)
Take with
food

2 tabs 2
times per
day
(Breakfast
and Lunch)
Take with
food

Zofran (Ondansetron)
8 mg by mouth every 8
hours for Nausea
*

8 am
4pm
10pm

Compazine
(Prochlorperazine)
10mg by mouth every 68 hours for Nausea
*
Ativan (Lorazepam)
1 mg by mouth at
bedtime for nausea and
anxiety
*
Decadron
(Dexamethasone) 4mg
by mouth to alleviate
swelling, prevent
nausea and vomiting

Day After
Chemo

2 tabs 2
times per
day
(Breakfast
and Lunch)
Take with
food

*You may continue to take as needed after Day 3 post treatment.

4/3/2020

Miscellaneous
Information
Side effects are:
Headaches and constipation

Helps to prevent allergic
reactions and may help to
increase appetite. May
cause insomnia
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Appendix S: Bay Area Wigs

Bay Area Wig & Hairpiece Source
This is a list of vendors who supply wigs and hairpieces recommended by patients. Stanford does not endorse any commercial
enterprises

Face to Face hair salon (custom hair pieces and wigs)
157 W Portal Ave #1
San Francisco, CA 94127
415.566.2806
Hair replacement by Janet (custom hair pieces and wigs)
1371 Laurel St.
San Carlos, CA 84070
659.592.3691
Hansen Fontana Inc. (Hair wigs/cranial prosthesis. Fully custom made or predesign wigs)
536 Bryant Street
San Francisco, CA 94107
414.495.8888 or 800.495.8881
The Wig Source at John Muir women’s health center (only in twice a month. Used and new wigs. Appt only)
1656 N. Calif Blvd.
Walnut Creek, CA 94596
925.947.5328
Marzel’s Inc. (breast prosthesis, surgical bras, lymphedema, synthetic wig pieces)
5980 Stoneridge Dr. Suite 119
Pleasanton, CA 94588
925.227.1402
1220 Oakland Blvd.
Walnut Creek, CA 94596
925.939.2450
Paris Fashion Wigs (storefront wigs, no custom wigs)
568 S Murphy Ave
Sunnyvale, CA 94086
408.737.2504
House of Wigs (hair for every women)
238 Plaza Central
Los Altos, CA 94022
650-559-00073
American Cancer Society (some free and donated wigs)
1720 S Amphlett Blvd.
San Mateo, CA
650.578.9902
1715 S Bascom
Campbell, CA
408.879.1032
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